KR20190034550A - 간성 뇌병증의 치료 방법 - Google Patents

간성 뇌병증의 치료 방법 Download PDF

Info

Publication number
KR20190034550A
KR20190034550A KR1020197002991A KR20197002991A KR20190034550A KR 20190034550 A KR20190034550 A KR 20190034550A KR 1020197002991 A KR1020197002991 A KR 1020197002991A KR 20197002991 A KR20197002991 A KR 20197002991A KR 20190034550 A KR20190034550 A KR 20190034550A
Authority
KR
South Korea
Prior art keywords
biotin
hepatic encephalopathy
treatment
patient
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197002991A
Other languages
English (en)
Korean (ko)
Inventor
프레데릭 세델
Original Assignee
메드데이 파마슈티컬스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메드데이 파마슈티컬스 filed Critical 메드데이 파마슈티컬스
Publication of KR20190034550A publication Critical patent/KR20190034550A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197002991A 2016-07-29 2017-07-28 간성 뇌병증의 치료 방법 Withdrawn KR20190034550A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305989.2A EP3275439A1 (en) 2016-07-29 2016-07-29 Method for treating hepatic encephalopathy
EP16305989.2 2016-07-29
PCT/EP2017/069194 WO2018020010A1 (en) 2016-07-29 2017-07-28 Method for treating hepatic encephalopathy

Publications (1)

Publication Number Publication Date
KR20190034550A true KR20190034550A (ko) 2019-04-02

Family

ID=56618106

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197002991A Withdrawn KR20190034550A (ko) 2016-07-29 2017-07-28 간성 뇌병증의 치료 방법

Country Status (24)

Country Link
US (2) US10117854B2 (https=)
EP (2) EP3275439A1 (https=)
JP (1) JP2019522030A (https=)
KR (1) KR20190034550A (https=)
AU (1) AU2017303346A1 (https=)
BR (1) BR112019001178A2 (https=)
CA (1) CA3031302A1 (https=)
CY (1) CY1122348T1 (https=)
DK (1) DK3319601T3 (https=)
EA (1) EA201990413A1 (https=)
ES (1) ES2751154T3 (https=)
HK (1) HK1254833B (https=)
HR (1) HRP20191798T1 (https=)
HU (1) HUE046590T2 (https=)
IL (1) IL264460B (https=)
LT (1) LT3319601T (https=)
MA (1) MA42419B1 (https=)
ME (1) ME03520B (https=)
PL (1) PL3319601T3 (https=)
PT (1) PT3319601T (https=)
RS (1) RS59300B1 (https=)
SI (1) SI3319601T1 (https=)
SM (1) SMT201900628T1 (https=)
WO (1) WO2018020010A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
MX387893B (es) * 2018-04-18 2025-03-19 Alparis Sa De Cv Nuevas fases solidas de rifaximina.
CN116173182A (zh) * 2023-03-31 2023-05-30 苏州融析生物科技有限公司 醋酸格拉替雷药物组合物在肝硬化预防及治疗药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788304B2 (ja) * 1988-03-05 1995-09-27 三生製薬株式会社 高アンモニア血症治療剤
US5814650A (en) * 1992-09-28 1998-09-29 Lifegroup S.P.A. Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions
DE20202562U1 (de) * 2002-02-19 2002-05-23 Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
CA2910717C (en) 2013-04-29 2021-01-26 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
CN105614851A (zh) * 2015-12-27 2016-06-01 劲膳美生物科技股份有限公司 肝性脑病医学配方食品
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy

Also Published As

Publication number Publication date
ES2751154T3 (es) 2020-03-30
CY1122348T1 (el) 2021-01-27
DK3319601T3 (da) 2019-11-18
HRP20191798T1 (hr) 2019-12-27
SMT201900628T1 (it) 2020-01-14
US10328059B2 (en) 2019-06-25
ME03520B (me) 2020-04-20
CA3031302A1 (en) 2018-02-01
BR112019001178A2 (pt) 2019-04-30
EP3275439A1 (en) 2018-01-31
IL264460B (en) 2021-06-30
AU2017303346A1 (en) 2019-01-31
EP3319601B1 (en) 2019-08-28
HK1254833B (en) 2020-05-22
EA201990413A1 (ru) 2019-06-28
PL3319601T3 (pl) 2020-06-29
LT3319601T (lt) 2019-11-11
PT3319601T (pt) 2019-09-18
WO2018020010A1 (en) 2018-02-01
JP2019522030A (ja) 2019-08-08
US10117854B2 (en) 2018-11-06
US20190070150A1 (en) 2019-03-07
MA42419B1 (fr) 2019-11-29
EP3319601A1 (en) 2018-05-16
HUE046590T2 (hu) 2020-03-30
SI3319601T1 (sl) 2019-11-29
RS59300B1 (sr) 2019-10-31
IL264460A (en) 2019-02-28
US20180214417A1 (en) 2018-08-02
MA42419A (fr) 2018-05-16

Similar Documents

Publication Publication Date Title
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
JP6913137B2 (ja) 新規２，４−ジニトロフェノール製剤およびその使用法
US7834056B2 (en) Pharmaceutical composition for gout
US11607389B2 (en) Delayed release deferiprone tablets and methods of using the same
AU2017279592A1 (en) Prophylactic or therapeutic agent for idiopathic inflammatory myopathies
KR20190034550A (ko) 간성 뇌병증의 치료 방법
JP2002507211A (ja) ジヒドロホノキオール組成物の合成
HK1254833A1 (en) Method for treating hepatic encephalopathy
KR20120104574A (ko) 티보자닙과 템시롤리무스의 조합물
EP4554589A1 (en) Solid oral dosage form comprising vortioxetine and vitamin d
TWI662967B (zh) 食後期之胃運動亢進劑
MX2015003810A (es) Metadoxina para usarse en el tratamiento de enfermedades hepaticas y formulaciones de liberacion prolongada de metadoxina.
HK1225607B (en) Sustained-release pharmaceutical composition comprising 2,4-dinitrophenol

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190129

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200722

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20210608

WITB Written withdrawal of application